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consequent inefficiency. This inefficiency is compounded by
poor success in following up women with abnormal smears.
To be effective, a screening programme should aim to
maximise coverage through a systematic and efficient
process, rather than increase the frequency of screening."
WHO recommendations for developing countries are to aim
initially to screen every woman once in her lifetime at the
age of about 40 years." With greater resources the
frequency of screening may be increased to once every 10
years, and then to once every 5 years for women between
the ages of 35 and 55 years."
The level of resources currently expended on screening in
Khayelitsha indicates that services should aim initially to
screen each woman once in her lifetime. This strategy's
increased yield, through maximisation of coverage, will result
in greater cost-effectiveness than the provision of repeat
smears to a smaller number of women in order to improve
the sensitivity of cytology screening. The distribution of age
at presentation indicates that this screening should take
place between 35 and 40 years of age. Measures to improve
follow-up should be emphasised. The basic principles of
primary health care (accessibility, acceptability, availability,
affordability) should be applied in the quest to achieve
maximum coverage, which is the first major target. Improved
coverage of higher-risk groups has major implications for the
organisation and provision of primary care services in similar
settings throughout South Africa.
We thank Shona Wilson for extracting the data for this study,
and Professor Jonny Myers and Or Leslie London for reviewing
early drafts of the article.
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A report on the status quo
H. W. Hitzeroth, C. E. Niehaus, D. C. Brill
During the 1980s a pilot newborn screening programme
for the early detection (and treatment) of amino
acidopathies, especially phenylketonuria (PKU), was
conducted by the Department of National Health and
Population Development. The motivation for this pilot
programme was the high priority accorded PKU screening
in Europe and North America and the presumed similarly
high incidence of this condition among South Africans of
European origin. From a cohort of 59 600 newborns
screened in the Pretoria area over a period of 8
consecutive years (1979 - 1986), only 1 case of PKU (and
1 of tyrosinaemia) was found. Statistically this result is
compatible (Poisson distribution, 95% confidence interval)
with a 'true' incidence of not more than 3/59 600 (or about
1/20000) newborns. It is concluded from this result and
other relevant information that newborn screening for PKU
and other amino acidopathies is not cost-effective and
justifiable, especially against the background of prevailing
demographic conditions and more pressing health
priorities in South Africa. This particular screening
programme was discontinued in 1986. The results and
conclusions are presented here. for the record.
S Atr Med J 1995; 85: 33-36.
Phenylketonuria (PKU) is a well-known, inherited metabolic
disease. It has attained a high profile in the context of
medicogenetic preventive services: because, among other
reasons, it is known to cause severe and irreversible mental
retardation;'·2 its incidence among newborns in western
Europe and North America is such that it warrants
interventional programmes (fable I); it can be diagnosed pre-
clinically by means of neonatal screening and subsequent
specific laboratory tests;,,3-5 and its serious sequelae,
including mental retardation, are preventable by early dietary
treatment'·· Before the advent of newborn screening
programmes for the prevention of PKU, relatively high
numbers of patients in centres for the mentally handicapped
owed their institutionalisation to this genetic disease.,-g
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Table I. Incidence of PKU in some countries/populations, as
relevant for South Africa""'"
Austria 1:8200 Scotland 1:6000
Australia 1:9000 The Netherlands 1:17 000
Belgium 1:6 000 - 8 100 New Zealand 1:16000
England 1:19000 USA (whites) 1:14000
Ireland 1:4 500 - 7 700 USA (blacks) 1:50000
Comprehensive and effective newborn screening
programmes for the prevention of PKU began to be
implemented on a state- (Massachusetts, USA) and country-
wide scale in the early 1960s. These have in the meantime
become accepted generally as part of routine primary health
care services in many countries, where this has been
recognised as a cost-effective and affordable priority. The
impact of such screening programmes over time has been
to reduce dramatically the incidence of new cases of PKU in
mental institutions, e.g. in the USA and Canada."·11
The white population of South Africa is primarily of
western European origin with its well-known, relatively high
incidences of PKU (Table I). It was therefore a plausible
working hypothesis that PKU should be as common among
the descendants of the European immigrants to South
Africa, as among their populations of origin. This implied
that it would be worthwhile to consider implementing a pilot
newborn screening programme for investigating the cost-
effectiveness and feasibility of more formal and
comprehensive screening programmes for the prevention of
PKU in South Africa, if found to be warranted. The first PKU
screening programme in South Africa was launched in
Johannesburg and continued for about 3 years (1964 - 1967)
(personal communication - Johannesburg City Health
Department, 1989). The test procedure comprised the
Phenistix test on urine specimens of babies aged
approximately 2 - 3 weeks (first test) and 6 weeks (repeat
test). These were performed by health visitors in private
homes. In total, about 36 000 babies underwent the first test
and about 30 800 both tests; these were performed mostly
on white (about 90%), but later also on brown and Asian
babies (about 10%). Although some babies were found to
be 'positive' or to have an indeterminate result on the
screening test, these results were not confirmed on
subsequent specific tests. Hence, no PKU baby was
diagnosed from this screening programme (and no 'missed'
cases were subsequently detected from this cohort of
newborns). However, as is well known today, the Phenistix
technique is insufficiently sensitive and many positive PKU
cases may be 'missed' by this test. The point was also
made that the Johannesburg screening programme had not
convincingly ascertained the incidence of PKU in South
African whites. '2
Against this background it became more important at that
time again to address the question of the incidence of PKU
in South Africa, and to explore strategies required for its
prevention, if found justifiable. For the period 1979 - 1981,
Genetic Services of the then Department of Health and
Welfare embarked on an exploratory neonatal screening
programme, inter alia for the detection of PKU. This was
then superseded by a more formal screening programme
(February 1981 - October 1986). The present communicatiqn
presents the results of these screening programmes for the
sake of the record, and attempts to establish the most likely
incidence of PKU in South African whites. As will be shown,
the results do not justify a newborn screening programme
for PKU in terms of cost-effectiveness and other competing
health priorities in South Africa. A tentative alternative option
to newborn screening, Le. appropriate and specialised
preventive services for high-risk PKU families (as is the case
with many other genetic diseases), is presented for
consideration.
Subjects and methods
For logistical reasons it was decided to implement the
screening programme in the Pretoria area, and to
concentrate initially on white babies because of the
suspected higher incidence of PKU within this population
group (see Discussion). It was endeavoured, as a matter of
routine, to include all consecutive (unselected) babies :
delivered in the five maternity clinics serving the selected
area. As required for PKU (and other feeding-dependent
metabolic disorders), the blood specimens were taken at
3 - 5 days of age, by way of heel-prick and blood-spotting
on standard filter paper cards. The collection technique,
handling, storage and testing procedure complied with the
requirements of the adopted methodology. The laboratory
assay was usually done within a week of collection, and
entailed the standard thin-layer chromatography (TLC)
technique for the detection of phenylalanine (for PKU), and
other metabolites for the detection of a variety of other
amino acidopathies. TLC performed for this purpose and as
an equivalent alternative to the Guthrie test was the method
of choice at that time," as also used in the screening
laboratory at Great Ormond Street Hospital for Sick
Children, London (where one of us, CEN., had obtained
first-hand laboratory experience).
The regulations of the then Department of Health and
Welfare (as well as of the subsequent Department of
National Health and Population Development) require tender
quotations for the laboratory tests, to be done according to
accepted specifications. The successive tenders (renewed
at intervals of 2 years) were awarded first to one particular
private pathology laboratory (for the duration of the
exploratory phase: 1979 - 1981) and thereafter to another
one (1981 - 1986), both in Pretoria. The major part of the
latter, formal phase of the screening programme was
conducted under the technical supervision of one of us
(CEN.). The sampling and laboratory procedures have also
been discussed in greater detail in the context of screening
for congenital hypothyroidism. t<
Results
During the exploratory phase (1979 - 1981) approximately
14 000 newborns were screened for PKU and other amino
acidopathies (as well as congenital hypothyroidism). Within
this period 1 case of PKU was diagnosed clinically in
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Pretoria. On checking this patient's record it was discovered
that she had been tested as a newborn and found negative
at the very beginning of the experimental screening phase
(September 1979). She therefore represents a false-negative
or 'missed' case.15 During the more formal continuation of
the screening programme at the second private pathology
laboratory (1981 - 1986), another 45 600 newborns were
screened and no cases of PKU were found. Private
paediatricians in Pretoria, as well as the Department of
Paediatrics of the University of Pretoria, were generally
aware of the screening programme. It was expected that any
'missed' cases would come to the attention of their
respective practices/clinics, as had been the case during the
exploratory phase. '5 However, no further 'missed' cases of
PKU came to our attention during the subsequent years. Of
the other amino acidopathies screened for, only 1 case of
tyrosinaemia was found among the cohort of 45 600
newborns.
Discussion
From the results as presented it follows that 1 PKU case
was born from among some 14 000 newborns (experimental
phase) and none was found among the 45 600 subsequent
newborns of the second phase. On statistical analysis using
the Poisson distribution, it follows that a combined
incidence of 1 PKU case found in 59 600 newborns is
compatible (within the 95% confidence interval) with a 'true'
incidence of not more than 3 such cases from among that
number of newborns.
From the screening experience evaluated here, the
tentative conclusion is that the incidence of PKU in the
Pretoria area (and possibly among South African whites in
general) seems to be considerably less than in their
European populations of origin. The incidence of PKU in
South African blacks, browns and Indians has yet to be
determined. Screening data on black and Indian populations
in other countries,·,6 show PKU to be considerably less
common in these racial groups than among whites. From
local clinical experience, tentative observations (informal
personal communications) suggest that while white PKU
patients are occasionally seen, only 1 black patient has been
diagnosed in this country.17
Whereas biochemical screening surveys of inmates of
institutions for the mentally handicapped in western Europe
and North America before the advent of newborn screening
and prevention showed PKU to be the most common of
such metabolic disorders (1 - 3% of all institutionalised
patients?·9), the equivalent incidences for this country are far
lower. Biochemical screening surveys at two large and
representative South African Care and Rehabilitation
Centres for white patients gave the following results:
(I) PotchefstroomlWitrand: 1 568 patients screened, 1,29%
found to have a metabolic disorder and 0,13% (2 patients)
PKU;,B.,9 (iJ) Cape Town/Alexandra: 1 087 patients screened,
0,6% found to have a metabolic disorder and 0,28% (3
patients) PKU!O
A similar screening programme at the Rand West (Millsite)
institution for mentally retarded black patients showed that
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of 267 patients screened, none had PKU and only 1 had a
detectable metabolic disorder.21
The tentative clinical observations, as well as the data
from mental institutions summarised above, support the
conclusion drawn from the results of the newborn screening
programmes presented here. PKU seems much less
common among whites than elsewhere, and particularly
rare among blacks, browns and Indians of this country
(Table I).
Given the above conclusion it was decided that screening
for PKU for any population group in South Africa was neither
cost-effective nor justifiable, especially against a
background of other, more pressing health priorities. The
newborn screening programme for PKU and other amino
acidopathies was duly discontinued in 1986 and no such
programme is currently being conducted in South Africa (as
far as we know).
Over recent years as many as 20 PKU families, each with
one or more affected children of different ages, have been
identified by anecdotal case finding (Genetic Services -
unpublished data). These represent high-risk families with a
known recurrence risk for PKU of 1 in 4. Such case-finding
and identification of at-risk families (as routinely done for
many other genetic diseases) provides opportunities for the
prevention of recurrences. This conventional strategy is
therefore an alternative option for identification of PKU in
South Africa in the absence of routine newborn screening.
The objective is to make appropriate information and
comprehensive genetic services, such as the following,
directly available to the families concerned, for their
voluntary utilisation: (I) ongoing clinical evaluations, genetic
counselling and dietary guidance for all affected (including
pregnant) PKU patients and their families; VI) the option of
having molecular-genetic investigations done for the
diagnosis of the underlying genetic defect and for the
detection of heterozygous carriers in as many family
members as would wish to avail themselves of this option;"
(iil) voluntary carrier tests on (would-be) spouses of
identified PKU heterozygotes; (iv) the option of a prenatal
test for the diagnosis of an affected fetus in high-risk PKU
pregnancies; (v) the offer to have newborn screening tests
done on all babies born to these (extended) families; and (vi)
guidelines for the dietary treatment of an affected baby (as
identified by the abovementioned individual newborn
screening test).
The comprehenSive, preventive genetic service as outlined
above is in keeping with what is being offered for many
other genetic diseases worldwide. PKU in South Africa
therefore reverts to the status of such a 'conventional'
genetic disease. It is suggested that the recommerided
approach provides an appropriately effective alternative
option for the prevention of PKU (given the local
circumstances and the present level of laboratory expertise),
in the absence of any large-scale newborn screening
programme in South Africa.
The authors would like to thank Professor 1. Jenkins
(Department of Human Genetics, SAIMR, Johannesburg) for his
comments on the manuscript.
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Micromanipulation at an
infertility centre
Aim. Human in vitro fertilisation (IVF) and gamete intra-
fallopian transfer have been used in the management of
various forms of infertility. In cases of severe male-factor
infertility, fertilisation can be a factor. In this study
micromanipulation was used to increase fertilisation in
such cases.
Methods. Two micromanipulation techniques, subzonal
sperm injection (SUZI) and partial zona dissection (PZD),
were used to assist fertilisation in patients with abnorTl)al
semen parameters. Ten couples with severe oligo-, terato-
and asthenozoospermia participated in the SUZI
programme. Seventy-three oocytes were obtained from
these 10 patients. PZD was used on day 1 oocytes in
cases of male infertility as well as a rescue attempt on day
2 oocytes when fertilisation had failed after routine
insemination.
Results. The SUZI technique had a fertilisation rate of
37,7%. In this group, a biochemical pregnancy was
achieved. Differences between the fertilisation rate of
conventionallVF (33,3%) and PZD (56,3%) in cases of
male infertility, were not statistically significant although a
clinical difference could be detected. PZD was statistically
effective in facilitating fertilisation (37,5% v. 8,3%) in
couples where this procedure was introduced to
reinseminate 24-hour-old unfertilised oocytes. Four
patients received PZD reinseminated embryos. An average
of 1,45 PZD embryos were replaced and 1 implantation
pregnancy was confirmed.
Conclusion. The micromanipulation results are
encouraging arid seemed to increase the efficiency of IVF
in humans. Furthermore, our data support the conclusion
that micromanipulation procedures can bring about
pregnancies.
S Afr Med J 1995; 85: 36-40.
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In vitro fertilisation (IVF) is effective in the management of a
variety of infertility problems. However, many cases of male
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